Pharmaceuticals News United Kingdom

Subscribe

Advertise your job ad
    Search jobs

    AstraZeneca buys US cancer drugs firm

    LONDON, UK: AstraZeneca said on Tuesday (27 August) that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceutical group seeks to bolster its flagging pipeline of new products.
    AstraZeneca buys US cancer drugs firm

    In terms of the deal, MedImmune will acquire 100% of Amplimmune's shares for an initial price of US$225m, with another US$275m deferrred until it reaches key drug development milestones.

    "AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to buy Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology," a statement said.

    "MedImmune's focus on harnessing the power of the patient's own immune system to fight cancer will be complemented by Amplimmune's innovative work in this area," said Bahija Jallal, executive vice president of MedImmune.

    "It will allow us to strengthen our arsenal of potential cancer therapies. We are excited to be working with the Amplimmune team to help find new treatments to address areas of medical need," Jallal said.

    Amplimmune is AstraZeneca's second acquisition under new chief executive Pascal Soriot, who joined in October last year. The London-listed group purchased US firm Pearl Therapeutics in June for US$1.15bn

    In a separate development, the world's top biotech firm Amgen agreed to buy Onyx Pharmaceuticals for US$10.4bn, joining a trend toward consolidation in the drug-making industry. The deal will allow Amgen to get its hands on Kyprolis, a promising treatment for blood cancer developed by Onyx and approved by US authorities in 2012.

    Source: AFP via I-Net Bridge

    Source: I-Net Bridge

    For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.

    We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field.

    Go to: http://www.inet.co.za
    Let's do Biz